small ubiquitin like modifier 3Genealiases: SMT3A · SMT3H1 · SUMO-3
Q-omics provides the consensus-scored SUMO3 profile across patient tissues and cancer cell-line models. SUMO3 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, SUMO3 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, SUMO3 protein abundance shows 22,089 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight UVM, HNSC, and PDAC as cancer lineages where SUMO3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SUMO3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SUMO3 survival associations across molecular data types. SUMO3 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (2) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SUMO3 RNA expression–survival associations across cancer types. High SUMO3 expression shows unfavorable associations in UVM, ACC, LAML and STAD, but favorable associations in KIRC and SKCM. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for SUMO3 RNA expression.
This table summarizes SUMO3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SUMO3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SUMO3 shows lower tumor expression in KICH and higher tumor expression in HNSC, LIHC, BLCA, LUSC and BRCA. The HNSC box plot shows higher SUMO3 RNA expression in tumor versus normal tissue (log2 FC = +1.118, t-test p < 0.001).
This table shows molecular features associated with SUMO3 in patient tissues and cancer cell lines. In patient samples, SUMO3 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, SUMO3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Leukemia.
